Literature DB >> 119352

Biotransformation of diclofenac sodium (Voltaren) in animals and in man. I. Isolation and identification of principal metabolites.

H Stierlin, J W Faigle, A Sallmann, W Küng, W J Richter, H P Kriemler, K O Alt, T Winkler.   

Abstract

1. The anti-inflammatory agent diclofenac sodium (o-[(2,6-dichlorophenyl)amino]phenylacetic acid sodium salt) is extensively metabolized by rat, dog, baboon and man. The main metabolites were isolated from the urine of all species and from the bile of rat and dog and identified by spectroscopy. 2. Metabolism involves direct conjugation of the unchanged drug, or oxidation of the aromatic rings usually followed by conjugation. Sites of oxidation are either position 3' or 4' of the dichlorophenyl ring or, alternatively, position 5 of the phenyl ring attached to the acetic acid moiety. 3. In the urine of rat, baboon and man conjugates of the hydroxylated metabolites predominate, but the major metabolite in dog urine is the taurine conjugate of unchanged diclofenac. 4. In the bile of rat and dog, the main metabolite is the ester glucuroniade of unchanged diclofenac.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 119352     DOI: 10.3109/00498257909042327

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  19 in total

Review 1.  Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls.

Authors:  N M Davies; K E Anderson
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

2.  Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.

Authors:  Ronald Esser; Carol Berry; Zhengming Du; Janet Dawson; Alyson Fox; Roger A Fujimoto; William Haston; Earl F Kimble; Julie Koehler; Jane Peppard; Elizabeth Quadros; Joseph Quintavalla; Karen Toscano; Laszlo Urban; John van Duzer; Xiaoli Zhang; Siyuan Zhou; Paul J Marshall
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

3.  Pharmacokinetics and metabolism of diclofenac sodium in Yucatan miniature pigs.

Authors:  R L Oberle; H Das; S L Wong; K K Chan; R J Sawchuk
Journal:  Pharm Res       Date:  1994-05       Impact factor: 4.200

4.  Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans.

Authors:  D J Carlile; N Hakooz; M K Bayliss; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

5.  Analysis of diclofenac and four of its metabolites in human urine by HPLC.

Authors:  R J Sawchuk; J A Maloney; L L Cartier; R J Rackley; K K Chan; H S Lau
Journal:  Pharm Res       Date:  1995-05       Impact factor: 4.200

6.  Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans.

Authors:  Julia Kirchheiner; Ingolf Meineke; Nadine Steinbach; Christian Meisel; Ivar Roots; Jürgen Brockmöller
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

7.  Possible mechanism by which the carbapenem antibiotic panipenem decreases the concentration of valproic acid in plasma in rats.

Authors:  S Kojima; M Nadai; K Kitaichi; L Wang; T Nabeshima; T Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

8.  Pharmacological properties of five diclofenac metabolites identified in human plasma.

Authors:  I Wiesenberg-Boettcher; J Pfeilschifter; A Schweizer; A Sallmann; P Wenk
Journal:  Agents Actions       Date:  1991-09

Review 9.  Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

10.  Preferential uptake of the non steroid anti-inflammatory drug diclofenac into inflamed tissues after a single oral dose in rats.

Authors:  A Schweitzer; N Hasler-Nguyen; J Zijlstra
Journal:  BMC Pharmacol       Date:  2009-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.